Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole

International Journal of STD and AIDS

Volumn 20, Issue 9, 2009, Pages 652-653

  Fisk, M ^a   Sage, E K ^a   Edwards, S G ^a   Cartledge, J D ^a   Miller, R F ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Co trimoxazole; Pneumocystis jirovecii; Toxicity; Treatment failure

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; STEROID;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD TOXICITY; DRUG ERUPTION; DRUG FEVER; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN TENSION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOMITING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; MALE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 69949185399     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.008470     Document Type: Article

References (10)

1. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986;105:37-44
2. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med 1988;109:280-287 (Pubitemid 18209887)
3. Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 1992;6:301-305
4. Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983;2:1109-1111
5. Hughes WT, Lafon SW, Scott JD, Masur H. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis 1995;171:1295-1301
6. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-499 (Pubitemid 14126737)
7. Benfield T, Atzori C, Miller RF, Helweg-Larsen J. Second-line salvage therapy of AIDS-associated Pneumocystis jirovecii pneumonia. J Acquir Immune Defic Syndr 2008;48:63-67
8. Walzer PD, Evans HER, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008;46:625-633
9. Gill HJ, Maggs JL, Madden S, Pirmohamed M, Park BK. Co-administration of fluconazole (but not ketoconazole) to healthy volunteers inhibits oxidation of sulphamethoxazole to the hydroxylamine metabolite. Br J Clin Pharmacol 1996;42:347-353
10. National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents (2008). http://aidsinfo.nih.gov/contentfiles/Adult-OI.pdf (last accessed 18 November 2008)